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Abstract
The starting point, in Marfan syndrome (MFS) appears to be the mutation of fi brillin-1 gene 
whose deconstructed protein product cannot bind transforming growth factor beta (TGF-b), 
leading to an increased TGF-b tissue level. The aim of this review is to review the already 
known features of the cellular signal transduction downstream to TGF-b and its impact on 
the tissue homeostasis of microfi brils, and elastic fi bers. We also investigate current data on 
the extracellular regulation of TGF-b level including mechanotransduction and the feedback 
cycles of integrin-dependent and independent activation of the latent TGF-b complex. Together 
these factors, by the destruction of the connective tissue fi bers, may play an important role in 
the development of the diverse cardiac and extracardiac manifestations of MFS and many of 
them could be a target of conservative treatment. We present currently investigated drugs for the 
treatment of the syndrome, and explore possible avenues of research into pathogenesis of MFS 
in order to improve understanding of the disease. (Cardiol J 2013; 20, 3: 227–234)
Key words: Marfan syndrome, aortic aneurysm, transforming growth factor-
-beta (TGF-b), matrix-metalloprotease (MMP)
Introduction
Marfan syndrome (MFS) is an inherited auto-
somal-dominant disease of the connective tissue 
[1]. In most cases, mutation of fibrillin 1 gene 
(FBN1) can be identifi ed [2]. This gene produces 
fi brillin 1 protein, which is the main constituent 
of microfi brils in the extracellular matrix. These 
fibres play an important role in incorporating 
elastin into elastic fi bres [3]. FBN1 gene is located 
at a chromosomal position of 15q21.1, and shows 
more than 1000 variation in mutation associated 
with different syndromes (MFS, acromicric dys-
plasia, geleophysic dysplasia 2, MASS syndrome, 
Shprintzen-Goldberg syndrome, Stiff skin syn-
drome, Weill-Marchesani syndrome 2) [1]. These 
mutations lead to impaired protein synthesis and 
secretion, or defective incorporation into the con-
nective tissue [2]. FBN1 mutation thus results in 
disintegration and fragmentation of connective 
tissue fi bres leading to tissue fragility and elon-
gation. Some syndrome manifestations can be 
directly ascribed to these structural abnormalities 
[2]. For genotype-phenotype analysis, mutations 
were divided into three groups: missense mutation, 
nonsense mutation and frameshift mutation [4]. 
Knowledge of the type and location of an FBN1 
mutation may be useful in providing further clinical 
correlation regarding phenotypic progression and 
appropriate medical management [5].
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In MFS, the fragility of the connective tissue 
weakens the ability of the aortic wall to withstand 
intraluminal pressure and aneurysm formation may 
result [6]. The extravascular manifestations such 
as joint hyperfl exibility and ocular lens ectopy are 
probably also related to the connective tissue disor-
der [6]. It is probable that MFS induces endothelial 
dysfunction as well: endothelial cell adherence una-
voidably requires microfi brils with intact structure 
and fi brillin 1 protein [7], and structural disruption 
in this context leads to defective adhesion and sub-
sequent endothelial abnormalities in the arteries 
[7]. Though fi brillin 1 protein defect plays a role 
in some of the extracardiac manifestations, the 
typical musculo-skeletal appearances may be cau-
sed by other molecular pathological mechanisms, 
including elevated TGF-b levels.
Marfan syndrome from 
a novel point of view
The fi rst step in the pathogenesis of MFS is 
the production of the altered protein product of the 
mutated FBN1 gene which results in the disruption 
of microfi brils and elastic fi bers [5]. Therefore to 
understand the exact pathological mechanism, and 
to fi nd salvage mechanisms for defective fi brillin-1, 
it is crucial to be familiar with the homeostasis 
of microfi brils and elastic components, a subject 
which has received relatively little attention de-
spite its clinical and scientifi c importance.
The link between fi brillin-1 homeostasis and 
a new molecular family, called ADAMTS (A Disin-
tegrin And Metalloproteinase ThromboSpondin 
motifs) has been recently studied. Mutations in 
ADAMTS10 and fi brillin-1 genes cause Weill-Mar-
chesani syndrome [8]. One feature, lens ectopy is 
common to both syndromes, while several features 
of Weil-Marchesani syndrome are the opposite of 
those that typical to MFS including brachydactyly, 
small stature and stiff joints [9]. Dysfunction of 
ADAMTS leading to dislocated lens has been de-
scribed in another study [10]. Apart from ADAMTS 
10, isolated mutation of ADAMTS4 also causes 
lens ectopy [10]. ADAMTS 10 binds to fi brillin-1 
with high affi nity and appears to be indispensable 
to microfi bril biogenesis [11]. Others demonstrated 
that proper structure and connection of the two 
proteins is necessary for the correct construction 
of the microfi brillar system [12]. The ADAMTSL6b 
protein was reported to play an essential role in 
connective tissue structure and regeneration [13]. 
Expression of ADAMTSL6b improved microfi bril 
impairment following periodontal ligament injury 
in a Marfan mouse model, and it also stimulates 
microfi bril regeneration [13]. Moreover, the le-
vel of TGF-b released in high concentration is 
reduced in the periodontal ligaments right after 
ADAMTSL6b administration [13]. Present data 
may prove a  fundamental role of ADAMTSL6b 
in restructuring fi brillin-1 associated microfi brils 
[13]. These results suggest that a novel therapeutic 
strategy can be designed for the treatment of MFS 
based upon the knowledge of ADAMTS 10- and 
ADAMTSL6b-mediated microfi bril biogenesis.
The role of TGF-b in the manifestations 
of Marfan syndrome
The failure of physiological processes like 
remodeling and salvage of microfibrils and the 
associated rise in the plasma level of the active 
TGF-b lead to the well-known manifestations of 
the syndrome.
Chaudhry et al. [14] stated in 2007, that muta-
tion of fi brillin 1 alters intercellular communication, 
and signifi cantly increases TGF-b protein level 
in the extracellular space. TGF-b is a paracrine 
regulatory molecule of several processes, inclu-
ding embryonic development, cell growth and 
apoptosis induction [15]. Among others, it also 
enhances collagen production and extracellular 
matrix (ECM) remodeling [16]. Although its effect 
is concentration-dependent, it is also affected by 
other factors beyond mere quantity in the tissue. 
TGF-b is produced in dimer form in the cells and 
is being bound with latency-associated protein 
(LAP) to form small latent complex (SLC) [16]. 
This secreted SLC is bound extracellularly to latent 
TGF-b binding protein (LTBP) to form large latent 
complex (LLC) [16]. LLC is then attached to mic-
rofi brils of fi brillin-1 by LTBP. The “latency” part 
in the nomenclature of these molecules refl ects 
their functional role in maintaining the inactive 
form of TGF-b [16].
TGF-b can only be activated by a series of 
organized and complex regulatory mechanisms, 
the appropriate function of which play a key role in 
human development. In MFS, fi brillin 1 mutation 
occurs, and LLC becomes unable to attach to micro-
fi brils [16]. Latent form is not generated, resulting 
in elevated serum TGF-b level [16]. TGF-b joins 
to its dimer receptor forming a complex which 
induces the phosphorylation cascade [16]. 
Another mutation in the TGF-b binding re-
ceptor 2 (TGFBR2) gene causes failure in signa-
ling pathways and results in the development of 
a Marfan-like syndrome called Marfan type II [16]. 
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So far the number of identified cases is small, 
but they also exhibit skeletal and cardiovascular 
manifestations similar to those in patients with 
FBN1 mutations [17]. The phenotypic differences 
between the mutations that can cause the variants 
of MFS (FBN1, TGFBR1, TGFBR2, TGFBR3) are 
diffi cult to distinguish, and there is a large overlap 
in the clinical presentation of these mutations [18]. 
Recently, mutations in TGFBR3 were also linked to 
MFS [18]. According to Attias et al. [19] the clinical 
outcomes between classical and type II MFS appear 
similar and the prognosis depends on the strength 
of the expression of the genetic disease and the 
treatment rather than the presence of TGFBR2 
mutation [19].
TGF-b activation pathways
As a growing body of evidence supports the 
view that elevated TGF-b levels may play a cen-
tral role in the development of the manifestations 
specific to MFS, all factors that can modulate 
active TGF-b levels should be studied in order to 
understand the diversity and variable expressivity 
observed in the phenotypes of the patients with 
the syndrome. One such factor is the activation 
of the latent TGF-b complex. Polymorphisms in 
gene-encoding molecules that participate in the 
activation process may be responsible for the va-
riable expressivity.
Among the known activating pathways pro-
teases, integrins, pH alteration and free oxygen 
radicals are all capable triggers for TGF-b activation 
[20–23]. TGF-b activation may occur by integrin-
independent, or integrin-related pathways. Pos-
sible mediators of integrin-independent TGF-b 
activation are matrix-metalloproteases (MMPs) 
playing a role in tissue remodeling via proteolysis 
of the extracellular matrix [24]. TGF-b release and 
activation by MMPs are well-recognized phenom-
ena. TGF-b activation is also infl uenced by pH, 
since latency-associated protein (LAP) disintegra-
tes in an acidic environment [20]. Although it is 
known from in vitro experiments that in extreme 
pH environments (pH 1,5 or 12) TGF-b activation 
signifi cantly increases, further research is needed 
to clarify the physiological role of this effect [20].
Another pathway of integrin-independent 
activation is the effect of reactive oxygen species 
(ROS) [21]. Fast activation of TGF-b happens by 
radiation, due to alteration of LAP and the molecule 
interaction [21]. Trombospondin-1 (TSP-1) is a cell 
glycoprotein, and its concentration may increase 
in conditions such as infl ammation leading to acti-
vation of dormant TGF-b [22]. 
Presently, there are two accepted modalities, 
which explain TGF-b1 activation by integrins 
containing bV. According to the fi rst one, confor-
mation alteration takes place in the inactive TGF-b 
complex induced by integrins resulting in an active 
form of TGF-b [23]. aVb6 integrin is known to be 
the fi rst TGF-b activator: when bound to the LAP 
arginine-glycine-aspartic acid (RGD) sequence, an 
alteration in conformation occurs, while the adhe-
sion-mediated effects of intercellular infl uences 
brings about TGF-b activation via a biochemical 
process [23]. This process happens in case of the 
high rigidity of the microfi brillar system, which 
is not capable of withstanding the shear stress, 
generated by integrin bonding. In these instances, 
integrin bound to RGD sequences excludes TGF-b 
from its complex [23, 25].
The other modality is the mechanism of pro-
tease-dependent activation of integrin. TGF-b can 
be activated by MMP-2 and MMP-9 by proteolytic 
degradation of the inactive (latent) TGF-b complex 
[26]. aV may enhance this process as it tightens 
the interaction of the molecules. Integrin aVb6 and 
aVb3 are simultaneously bound to latent TGF-b 
complex and to MMPs — as catalysts to speed up 
complex degradation [26]. In conclusion, from the 
perspective of MFS the mechanosensor function 
of TGF-b seems to be important. Elasticity of the 
microfi brillar system affects the extent of TGF-b 
release from the latent complex. When connective 
tissue is inelastic, the elevated active TGF-b level, 
by increasing the expression of certain proteases 
including MMPs, induces the remodelling of the 
ECM [24] (see below). This negative feedback 
cycle in the mechanosignalling process eventu-
ally allows the fi ne tuning of the connective tis-
sue elasticity [23]. The aforementioned activating 
modalities, by altering the tissue concentration of 
the active form of TGF-b, may affect the dynamic 
equilibrium maintained by the mechanotransduc-
tion feedback and thus modify the severity of the 
manifestations in MFS (Fig. 1) [23]. Therefore, 
better understanding of this function together 
with the clarifi cation of the possible role of gene 
polymorphisms, may help to explain the important 
phenotypical variations in Marfan patients. These 
modalities offer a potential research opportunity for 
the development of drugs to modify the course of 
MFS by diminishing TGF-b tissue levels.
TGF-b signal transduction pathways 
in Marfan syndrome
There are two distinct ways of intracellular 
signaling, through which elevated TGF-b level 
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can exert its detrimental effects: the so-called 
canonical and non-canonical signal transduction 
[27, 28]. The former pathway is mediated by the 
Smad proteins [27]. In MFS Smad2 protein plays 
an exclusive role [27]. By forming a complex with 
Smad4, CBP and P300 Smad2 regulates transcrip-
tion and induces MMP production (Fig. 2).
Gomez et al. concluded in 2011 [27] that the 
signalling pathway of TGF-b/Smad2 plays a crucial 
role in the development of thoracic aortic aneu-
rysms of different etiology. Increased expression of 
Smad2 may cause histological aortic wall changes. 
Epigenetic factors infl uence the expression levels 
of Smad2. Chromatin immunoprecipitation showed 
Figure 1. In this picture mechanotransduction mediated by the integrin dependent activation of latent transforming 
growth factor-beta (TGF-b) is illustrated. In part A no forces exerted on the large latent complex (LLC) composed of 
the inactive form of TGF-b, latency associated protein (LAP), and latent TGF-b binding protein (LTBP). In this steady 
state no TGF-b activation happens by mechanical forces. In part B and C mechanical forces arising from actin stress 
fibre mediated cell traction or other sources (e.g. aortic wall tension) are exerted on the LLC with through integrin 
molecules (Int). However in part B compliant extracellular matrix (ECM) adapts to this effect and no further TGF-b 
activation happens. Contrary in part C because of the resistant ECM no such adaptation happens causing the con-
formation change of the lap molecule and as a consequence the integrin mediated liberation of TGF-b. Active TGF-b 
through its receptor (TGFBR1-2) induces the expression of matrix metalloproteinases, including gelatinases (MMP-2 
and MMP-9) — which then can cleave the microfibrillar network, other fibre components in the ECM, and also LAP 
protein. The latter increases the activation of the latent TGF-b, thus a positive feedback cycle occurs. In part D cleaved 
ECM components and cleaved LAP are depicted as a result of the negative feedback regulation of the ECM compliance 
by integrin and TGF-b mediated mechanosignalling.
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H3K9/14 acetylation and H3K4 methylation resul-
ting in alteration of DNS histon proteins, fi nally 
leading to enhanced Smad2 expression [27]. 
ERKl/2 protein takes part in the regulation 
of Smad2-Smad4 complex, and may represent an 
important therapeutic target [29]. TGF-b activa-
tion induces the phosphorylation cascade in Jun 
N-terminal associated Kinase (JNK) p38/MAPK 
pathways as well. JNK activates c-JUN and c-FOS 
transcriptional factors in the cell nucleus [29]. 
Based on mice model experiments, JNK inhibition 
might be a therapeutic target, since blocking this 
pathway may reduce MMPs and mRNS, which play 
a role in Marfan pathology [29]. Erk1/2 inhibition 
is given emphasis in the publication, which partly 
explains losartan’s mechanism of action [29]. 
Besides, inhibiting the signalling pathway of p38-
-MAPK also reduces MMP level, while blocking 
ERK 1/2 pathway enhanced the level of membrane 
associated MMP inhibitors (Fig. 2) [30]. Because of 
confl icting data on the canonical and non-canonical 
pathways, it is not clear which is more important 
in the development of the manifestations of MFS.
The TGF-b pathway overactivity
High concentration of active TGF-b predo-
minates in the aforementioned mechanisms and 
leads to the different features of MFS. Thus, more 
collagen reduces the compliance of the aortic wall, 
which loses structural integrity and becomes dila-
ted and aneurysmal. High interstitial concentration 
of TGF-b is also responsible for reduced muscle 
mass, characteristic to Marfanoid habitus as TGF-b 
hinders mitosis and differentiation of satellite cells 
which are important in the development of muscle 
fi bres [31]. Moreover, a high TGF-b level inhibits 
the fusion of satellite cells [31] and the down-
stream signalling pathways of endogenous bone 
morphogenetic protein 2 (BMP-2) in human stem 
cells, which is indispensable for bone and cartila-
ge development [32]. Because of this interaction 
between BMP-2 and TGF-b, the high availability 
of the latter molecule may be responsible for the 
tall stature of Marfan patients and other Marfanoid 
features [32].
TGF-b upregulates the expression of elastase 
and many matrix-metalloproteases [33]. While 
an increased level of elastase enhances elastin 
degradation, MMPs seem to be responsible for 
the disintegration of elastic fi bres [33]. Therefore 
overproduction of these proteases reduces con-
nective tissue elasticity, and leads to weakness of 
the aortic wall. Connection of TGF-b levels and 
MMP expression has been studied in marfan mice 
model [33]. TGF-b increased mRNS expression of 
MMP-2, MMP-9 in mice [33]. Furthermore, in the 
MMP-12-defi cient mouse model, TGF-b-associated 
aortic aneurysm does not develop [34], indicating 
that MMP inhibition may prevent aortic pathology 
in MFS. Recently, MMPs have been studied in 
Marfan patients. Ikonomidis et al. [35] compared 
Figure 2. In this figure latent transforming growth factor-
-beta (TGF-b) activation, canonical and non-canonical 
TGF-b signalling are depicted. In the extracellular ma-
trix TGF-b which is secreted as a small latent complex 
(SLC) — containing latency associated protein (LAP) and 
a TGF-b dimer — binds to the latent TGF-b binding protein 
(LTPB) forming large latent complex (LLC). As illustrated 
in the figure LLC adheres to microfibrils built from fibril-
lin-1 proteins. In the intracellular space Smad mediated 
canonical signalling (red) and non-canonical (green) p38, 
extracellular signal-regulated kinase (ERK1/2), and Jun 
N-terminal associated kinase (JNK1) mediated pathways are 
shown. Genes upregulated by TGF-b signalling (MMPs — 
matrix metalloproteinases; PAI — plasminogen activator 
inhibitor) and target molecules of angiotensin receptor 
blockers (ARBs) through the AT-1 receptor of angiotensin 
II are also illustrated in the picture; TGFBR1-2 — TGF-b 
binding receptor 1-2; CBP/P300 — CREB-binding protein; 
RAS — rat sarcoma; TAK1 — TGF-b-activated kinase 1; 
MEK1 — mitogen activated protein kinase 1
232 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 3
MMP and TIMP levels of 9 patients with aortic 
aneurysm with those of 18 non-Marfan patients 
with aortic aneurysm. In Marfan patients MMP-
-12 level was high, while TIMP-3 level was low. 
In the non-Marfan group, signifi cantly lower level 
of MMP-1, MMP-3, MMP-8, MMP-9 and MMP-12 
were found [35], suggesting a major role of MMPs 
in the connective tissue destruction in the aortic 
wall [35].
Modalities of pharmacological 
treatment in Marfan syndrome
Understanding the basic elements of the 
syndrome paved the way to various therapeutic 
developments with a  view to pharmacological 
manipulations to reduce the deleterious effects 
of TGF-b. The first compound in such therapy 
was losartan, an angiotensin II receptor blocking 
agent (ARB) with antihypertensive effect [36]. 
Losartan reduces blood pressure by inhibiting the 
vasoconstriction produced when angiotensin II 
binds to its receptor, but in MFS a more important 
effect is to reduce TGF-b activity and remodelling 
[37]. Thus, inhibition of angiotensin receptor acti-
vity is a credible therapeutic measure. Losartan 
administration has shown promising results in 
modifying the development of characteristic Mar-
fan features in the mouse model [36]. This led to 
clinical trials in which a signifi cant reduction of 
the aortic diameter was observed over a 1–4 year 
interval with losartan and irbesartan [38, 39]. 
Based on these fi ndings, a multicenter study was 
set up in the Netherland with the involvement of 
330 Marfan patients [40]. Half were given losartan. 
Reduction of aortic diameter as measured by MRI 
is the primary endpoint, and Marfan-related death, 
aortic dissection, surgery, aortic stiffness and left 
ventricular dysfunction are secondary endpoints 
[40]. The results of this ongoing trial will provide 
valuable information about the effi cacy of losartan 
treatment, and a positive result may fundamentally 
modify the standard treatment of Marfan patients 
and their prognosis [40].
The mechanism of action for losartan is still 
hypothetical. Xiong et al postulated in 2012 that 
this mechanism may combine the inhibition of the 
ERK1/2 pathway and reduction of phosphorylated 
Smad2 levels [41] to inhibit aneurysm formation 
[41]. The publication also touches on the therapeu-
tic effect of doxycycline in reducing MMP-2 level 
[41]. Among others, this type of metalloproteases 
seems to play a role in aortic dilatation and annu-
loaortic ectasia.
In the MMP-2-defi cient mouse model designed 
for inhibition the activation of the TGF-b pathway and 
ERKl/2, Smad2 phosphorylation resulted in prolonga-
tion of life [42]. This means that doxycycline therapy 
may reduce MMP-2 level responsible for aneurysm 
formation by inhibiting the noncanoni cal pathway 
[42]. Doxycycline treatment in Marfan mice caused 
a signifi cant reduction in MMP-2 and MMP-9 levels 
and a reduction in aortic aneurysm progression and 
instances of aortic disruption [42]. 
Chung et al. [43] compared the use of the ate-
nolol (a frontline agent in the management of aortic 
aneurysm) and doxycycline, a recently recognized 
nonspecifi c, intracellular MMP inhibitor. Long-
-term follow up showed that doxycycline is more 
effective in secondary prevention of aneurysm 
formation [43]. Single and combined administra-
tion of losartan and doxycyline in Marfan mice 
[44] showed a synergistic effect in the combined 
treatment group. Reduction of TGF-b and MMP-2 
levels prevented aneurysm formation and impro-
ved elastic fi bre organization [44]. Based upon the-
se fi ndings, combined administration can be more 
effective in secondary prevention. The angiotensin 
converting enzyme inhibitor perindopril inhibits 
ECM remodeling [45]. In a randomised study of 
17 Marfan patients published in 2010, ten patients 
received perindopril and seven placebo. All had 
b-blockers [45]. The perindopril group experienced 
a reduction of TGF-b, MMP-2 and MMP-3 levels 
[45]. Most recently, pravastatin was reported ef-
fective in inhibiting intensifi ed protein synthesis 
in the smooth muscle cells of the aortic wall, and 
may be as effective as losartan in reducing aortic 
dilatation (Table 1) [46].
Conclusions
The study of the molecular pathogenesis of 
MFS may open new avenues in pharmocological 
therapy, which has the potential of delaying or 
avoiding high-risk and complex aortic surgery 
in these young and often asymptomatic patients. 
Further examination of the molecular mechanism 
of aortic dissection may identify reliable predictors 
to enable screening of these patients and optimal 
timing of preventive surgical intervention.
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